Evans, A., Davies, M., Osborne, V., Roy, D., & Shakir, S. (2020). Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study. PloS one, 15(10), e0240489. https://doi.org/10.1371/journal.pone.0240489
Citácia podle Chicago (17th ed.)Evans, Alison, Miranda Davies, Vicki Osborne, Debabrata Roy, a Saad Shakir. "Incidence of Major and Clinically Relevant Non-major Bleeding in Patients Prescribed Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation in Secondary Care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) Study." PloS One 15, no. 10 (2020): e0240489. https://doi.org/10.1371/journal.pone.0240489.
Citácia podľa MLA (8th ed.)Evans, Alison, et al. "Incidence of Major and Clinically Relevant Non-major Bleeding in Patients Prescribed Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation in Secondary Care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) Study." PloS One, vol. 15, no. 10, 2020, p. e0240489, https://doi.org/10.1371/journal.pone.0240489.